Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

David Brennan Appointed As Non-executive Director Of Reed Elsevier - Quick Facts

RELATED NEWS
Trade ENL now with 

Reed Elsevier Plc (ENL: Quote, REL.L) Thursday announced that Mr David Brennan has been appointed as a non-executive director of the company.

The company stated that David Brennan will assume office with effect from 1 November 2012, subject to shareholder approval at the respective Annual General Meetings to be held on 24 and 25 April 2012.

Mr Brennan is currently the Chief Executive Officer of AstraZeneca PLC, a global biopharmaceutical company, which develops, manufactures and markets prescription medicines.

Commenting on his appointment, Anthony Habgood, Chairman, said, "I would like to welcome David to Reed Elsevier. He has over 35 years experience in the biopharmaceutical industry and of the development, manufacture and commercialisation of innovative medicines. As a truly international executive with deep knowledge of the world's healthcare markets he will bring highly relevant experience to our board discussions….. '.

Click here to receive FREE breaking news email alerts for Reed Elsevier PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Toyota Motor Corp. (TM, TYT.L) Thursday announced 1.1 percent decline in worldwide production for October, as there was a sharp decline in production of passenger cars in Japan. Production outside Japan improved 2.3 percent. In a separate announcement, the Japanese automaker said it will recall more... Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.